Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth

Masayo Hosokawa, Kotoe Kashiwaya, Hidetoshi Eguchi, Hiroaki Ohigashi, Osamu Ishikawa, Mutsuo Furihata, Yasuhisa Shinomura, Kohzoh Imai, Yusuke Nakamura, Hidewaki Nakagawa

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows the worst mortality among the common malignancies and development of novel therapies for PDAC through identification of good molecular targets is an urgent issue. Among dozens of over-expressing genes identified through our gene-expression profile analysis of PDAC cells, we here report CST6 (Cystatin 6 or E/M) as a candidate of molecular targets for PDAC treatment. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical analysis confirmed over-expression of CST6 in PDAC cells, but no or limited expression of CST6 was observed in normal pancreas and other vital organs. Knock-down of endogenous CST6 expression by small interfering RNA attenuated PDAC cell growth, suggesting its essential role in maintaining viability of PDAC cells. Concordantly, constitutive expression of CST6 in CST6-null cells promoted their growth in vitro and in vivo. Furthermore, the addition of mature recombinant CST6 in culture medium also promoted cell proliferation in a dose-dependent manner, whereas recombinant CST6 lacking its proteinase-inhibitor domain and its non-glycosylated form did not. Over-expression of CST6 inhibited the intracellular activity of cathepsin B, which is one of the putative substrates of CST6 proteinase inhibitor and can intracellularly function as a pro-apoptotic factor. These findings imply that CST6 is likely to involve in the proliferation and survival of pancreatic cancer probably through its proteinase inhibitory activity, and it is a promising molecular target for development of new therapeutic strategies for PDAC.

Original languageEnglish
Pages (from-to)1626-1632
Number of pages7
JournalCancer Science
Volume99
Issue number8
DOIs
Publication statusPublished - Aug 25 2008
Externally publishedYes

Fingerprint

Cystatin M
Cysteine Proteinase Inhibitors
Pancreatic Neoplasms
Adenocarcinoma
Growth
Peptide Hydrolases
Null Lymphocytes
Cathepsin B
serpin B6
Reverse Transcriptase Polymerase Chain Reaction
Transcriptome
Small Interfering RNA
Culture Media
Pancreas
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hosokawa, M., Kashiwaya, K., Eguchi, H., Ohigashi, H., Ishikawa, O., Furihata, M., ... Nakagawa, H. (2008). Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Science, 99(8), 1626-1632. https://doi.org/10.1111/j.1349-7006.2008.00869.x

Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. / Hosokawa, Masayo; Kashiwaya, Kotoe; Eguchi, Hidetoshi; Ohigashi, Hiroaki; Ishikawa, Osamu; Furihata, Mutsuo; Shinomura, Yasuhisa; Imai, Kohzoh; Nakamura, Yusuke; Nakagawa, Hidewaki.

In: Cancer Science, Vol. 99, No. 8, 25.08.2008, p. 1626-1632.

Research output: Contribution to journalArticle

Hosokawa, M, Kashiwaya, K, Eguchi, H, Ohigashi, H, Ishikawa, O, Furihata, M, Shinomura, Y, Imai, K, Nakamura, Y & Nakagawa, H 2008, 'Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth', Cancer Science, vol. 99, no. 8, pp. 1626-1632. https://doi.org/10.1111/j.1349-7006.2008.00869.x
Hosokawa M, Kashiwaya K, Eguchi H, Ohigashi H, Ishikawa O, Furihata M et al. Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Science. 2008 Aug 25;99(8):1626-1632. https://doi.org/10.1111/j.1349-7006.2008.00869.x
Hosokawa, Masayo ; Kashiwaya, Kotoe ; Eguchi, Hidetoshi ; Ohigashi, Hiroaki ; Ishikawa, Osamu ; Furihata, Mutsuo ; Shinomura, Yasuhisa ; Imai, Kohzoh ; Nakamura, Yusuke ; Nakagawa, Hidewaki. / Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. In: Cancer Science. 2008 ; Vol. 99, No. 8. pp. 1626-1632.
@article{6bf6f14e31ad4ed793fade47da40e575,
title = "Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) shows the worst mortality among the common malignancies and development of novel therapies for PDAC through identification of good molecular targets is an urgent issue. Among dozens of over-expressing genes identified through our gene-expression profile analysis of PDAC cells, we here report CST6 (Cystatin 6 or E/M) as a candidate of molecular targets for PDAC treatment. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical analysis confirmed over-expression of CST6 in PDAC cells, but no or limited expression of CST6 was observed in normal pancreas and other vital organs. Knock-down of endogenous CST6 expression by small interfering RNA attenuated PDAC cell growth, suggesting its essential role in maintaining viability of PDAC cells. Concordantly, constitutive expression of CST6 in CST6-null cells promoted their growth in vitro and in vivo. Furthermore, the addition of mature recombinant CST6 in culture medium also promoted cell proliferation in a dose-dependent manner, whereas recombinant CST6 lacking its proteinase-inhibitor domain and its non-glycosylated form did not. Over-expression of CST6 inhibited the intracellular activity of cathepsin B, which is one of the putative substrates of CST6 proteinase inhibitor and can intracellularly function as a pro-apoptotic factor. These findings imply that CST6 is likely to involve in the proliferation and survival of pancreatic cancer probably through its proteinase inhibitory activity, and it is a promising molecular target for development of new therapeutic strategies for PDAC.",
author = "Masayo Hosokawa and Kotoe Kashiwaya and Hidetoshi Eguchi and Hiroaki Ohigashi and Osamu Ishikawa and Mutsuo Furihata and Yasuhisa Shinomura and Kohzoh Imai and Yusuke Nakamura and Hidewaki Nakagawa",
year = "2008",
month = "8",
day = "25",
doi = "10.1111/j.1349-7006.2008.00869.x",
language = "English",
volume = "99",
pages = "1626--1632",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth

AU - Hosokawa, Masayo

AU - Kashiwaya, Kotoe

AU - Eguchi, Hidetoshi

AU - Ohigashi, Hiroaki

AU - Ishikawa, Osamu

AU - Furihata, Mutsuo

AU - Shinomura, Yasuhisa

AU - Imai, Kohzoh

AU - Nakamura, Yusuke

AU - Nakagawa, Hidewaki

PY - 2008/8/25

Y1 - 2008/8/25

N2 - Pancreatic ductal adenocarcinoma (PDAC) shows the worst mortality among the common malignancies and development of novel therapies for PDAC through identification of good molecular targets is an urgent issue. Among dozens of over-expressing genes identified through our gene-expression profile analysis of PDAC cells, we here report CST6 (Cystatin 6 or E/M) as a candidate of molecular targets for PDAC treatment. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical analysis confirmed over-expression of CST6 in PDAC cells, but no or limited expression of CST6 was observed in normal pancreas and other vital organs. Knock-down of endogenous CST6 expression by small interfering RNA attenuated PDAC cell growth, suggesting its essential role in maintaining viability of PDAC cells. Concordantly, constitutive expression of CST6 in CST6-null cells promoted their growth in vitro and in vivo. Furthermore, the addition of mature recombinant CST6 in culture medium also promoted cell proliferation in a dose-dependent manner, whereas recombinant CST6 lacking its proteinase-inhibitor domain and its non-glycosylated form did not. Over-expression of CST6 inhibited the intracellular activity of cathepsin B, which is one of the putative substrates of CST6 proteinase inhibitor and can intracellularly function as a pro-apoptotic factor. These findings imply that CST6 is likely to involve in the proliferation and survival of pancreatic cancer probably through its proteinase inhibitory activity, and it is a promising molecular target for development of new therapeutic strategies for PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) shows the worst mortality among the common malignancies and development of novel therapies for PDAC through identification of good molecular targets is an urgent issue. Among dozens of over-expressing genes identified through our gene-expression profile analysis of PDAC cells, we here report CST6 (Cystatin 6 or E/M) as a candidate of molecular targets for PDAC treatment. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical analysis confirmed over-expression of CST6 in PDAC cells, but no or limited expression of CST6 was observed in normal pancreas and other vital organs. Knock-down of endogenous CST6 expression by small interfering RNA attenuated PDAC cell growth, suggesting its essential role in maintaining viability of PDAC cells. Concordantly, constitutive expression of CST6 in CST6-null cells promoted their growth in vitro and in vivo. Furthermore, the addition of mature recombinant CST6 in culture medium also promoted cell proliferation in a dose-dependent manner, whereas recombinant CST6 lacking its proteinase-inhibitor domain and its non-glycosylated form did not. Over-expression of CST6 inhibited the intracellular activity of cathepsin B, which is one of the putative substrates of CST6 proteinase inhibitor and can intracellularly function as a pro-apoptotic factor. These findings imply that CST6 is likely to involve in the proliferation and survival of pancreatic cancer probably through its proteinase inhibitory activity, and it is a promising molecular target for development of new therapeutic strategies for PDAC.

UR - http://www.scopus.com/inward/record.url?scp=49749117101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749117101&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00869.x

DO - 10.1111/j.1349-7006.2008.00869.x

M3 - Article

VL - 99

SP - 1626

EP - 1632

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -